FluMist May Require Additional Phase III Trial To Expand Patient Population

MedImmune seeks to expand the indication for its intranasal flu vaccine to people ages 50 to 64; the company is waiting to see if FDA will accept new analyses of existing data in the target age group. MedImmune and Chiron suggest incentives to increase flu vaccine demand during a House committee hearing.